Beximco Pharmaceuticals Limited, one of leading pharmaceutical company based at Bangladesh, have completed its acquisition of the majority stake (54.6%) in Sanofi Bangladesh Limited.
About Sanofi Bangladesh
Sanofi Bangladesh is part of the wider group, Sanofi S.A., a global biopharmaceutical company focused on human health.
The operations in Bangladesh were established in 1958 as part of the British chemical company, May & Baker.
Following a series of mergers, it became known as Sanofi-Aventis in 2004, before being renamed Sanofi Bangladesh Limited in 2013.
Sanofi Bangladesh’s state-of-the-art manufacturing facilities, including a PIC/S certifiable manufacturing facility for the leading antibiotic, cephalosporin, are spread over 25 acres of land, located near Beximco Pharma’s manufacturing facility in Tongi. Sanofi Bangladesh produces approximately 100 branded generic products, predominately for the local market. The company has a strong presence in cardiology, diabetes, oncology, dermatology and CNS. Sanofi also supplies its global brands of vaccines, insulins and chemotherapy drugs to Bangladesh through direct imports.
Why this deal?
- The completion of this deal – the second acquisition in Beximco Pharma’s history – is a major milestone for Beximco.
- This acquisition, diversification will strengthen Beximco’s position in Bangladesh pharmaceutical market.
- The acquisition of a majority stake in Sanofi Bangladesh is precisely in line with this strategy, strengthening our position in key therapeutic areas to drive sustainable revenue and profit growth.